Dr Reddys Laboratories RDY
NYSE RDY
$11.84 -0.05 (-0.38%)
As of: Sep 9, 2026 · 2:09 PM EDT

Dr Reddys Laboratories (RDY) Income from Non-Controlling Interests (2009 - 2026)

Dr Reddys Laboratories (RDY) posted Income from Non-Controlling Interests of -$918960.0 for Q2 2026, down 2200.16% on a QoQ basis from $43756.6 in Q1 2026, and up 4.09% year-over-year from -$882853.0 in Q2 2025.

Analysis

Dr Reddys Laboratories (RDY) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends

Dr Reddys Laboratories has reported Income from Non-Controlling Interests for 11 years, with the latest figure at -$918960.0 in Q2 2026.

  • On a quarterly basis, Income from Non-Controlling Interests rose 4.09% year-over-year to -$918960.0 in Q2 2026; TTM through Jun 2026 was -$4.3 million, a 158.23% decrease from a year earlier, with the FY2026 full-year figure at -$4.4 million, down 152.46% from the prior year.
  • Income from Non-Controlling Interests was -$918960.0 for Q2 2026 at Dr Reddys Laboratories, down from $43756.6 in the prior quarter.
  • The five-year high for Income from Non-Controlling Interests was $10.3 million in Q3 2024, with the low at -$2.3 million in Q4 2025.
  • Average Income from Non-Controlling Interests over 3 years is $388801.5, with a median of -$938553.2 recorded in 2025.
  • The sharpest annual moves came in 2025 and 2026: Income from Non-Controlling Interests tumbled 111.59% in 2025, then soared 105.74% in 2026.
  • Over 3 years, Income from Non-Controlling Interests stood at -$1.1 million in 2024, then slumped by 101.6% to -$2.3 million in 2025, then soared by 59.49% to -$918960.0 in 2026.
  • The last three Income from Non-Controlling Interests figures came in at -$918960.0 (Q2 2026), $43756.6 (Q1 2026), and -$2.3 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Teva Pharmaceutical Industries 42.58 Bn 38.93 Bn 2.15 Bn -
2 Viatris 19.17 Bn 18.28 Bn 1.46 Bn -
3 Dr Reddys Laboratories 9.85 Bn 9.68 Bn 396.53 Mn -918,959.97
4 Amneal Pharmaceuticals 5.47 Bn 5.34 Bn 334.51 Mn 11.95 Mn
5 Bausch Health Companies 2.36 Bn 526.37 Mn 2.10 Bn 2.00 Mn
6 Alvotech 1.50 Bn 1.36 Bn 2.56 Mn -
7 Ani Pharmaceuticals 1.49 Bn 1.13 Bn 165.89 Mn -
8 Amphastar Pharmaceuticals 995.08 Mn 704.96 Mn 93.47 Mn -
9 Fennec Pharmaceuticals 408.84 Mn 367.59 Mn 17.15 Mn -
10 RedHill Biopharma 180.35 Mn 180.35 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -918,959.97
Mar 31, 2026 43,756.64
Dec 31, 2025 -2.27 Mn
Sep 30, 2025 -1.19 Mn
Jun 30, 2025 -958,146.34
Mar 31, 2025 -762,170.25
Dec 31, 2024 -1.13 Mn
Sep 30, 2024 10.29 Mn
Mar 31, 2018 46.97 Mn
Dec 31, 2017 51.67 Mn
Sep 30, 2017 44.33 Mn
Jun 30, 2017 9.17 Mn
Mar 31, 2017 -687,006.12
Dec 31, 2016 69.77 Mn
Sep 30, 2016 44.07 Mn
Jun 30, 2016 18.89 Mn
Mar 31, 2016 -3.26 Mn
Dec 31, 2013 -16,124.88
Sep 30, 2013 -16,126.93
Jun 30, 2013 -17,972.06